refametinib

An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein… (More)

Topic mentions per year

Topic mentions per year

2013-2017
02420132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purpose The MEK/MAPK pathway is commonly activated in HER2-positive breast cancer, but little investigation of targeting this… (More)
Is this relevant?
2017
2017
Aortic valve disease (AVD) is a common condition with a progressive natural history, and presently, there are no pharmacologic… (More)
Is this relevant?
2016
2016
Activating KRAS mutations are reported in up to 90% of pancreatic cancers. Refametinib potently inhibits MEK1/2, part of the MAPK… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2016
2016
PURPOSE To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor refametinib combined with sorafenib… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry… (More)
Is this relevant?
2015
2015
The multikinase inhibitor regorafenib (BAY 73-4506) exerts both anti-angiogenic and anti-tumorigenic activity in adult solid… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
2014
2014
PURPOSE There is an unmet need for treatment options in hepatocellular carcinoma (HCC). Sorafenib is currently the only approved… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
Purpose: There is an unmet need for treatment options in hepatocellular carcinoma (HCC). Sorafenib is currently the only approved… (More)
  • table 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
OBJECTIVE The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY… (More)
Is this relevant?
Review
2013
Review
2013
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?